These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31355511)

  • 1. Association of two BRM promoter polymorphisms and smoking status with malignant pleural mesothelioma risk and prognosis.
    Lee MJ; Kuehne N; Hueniken K; Liang S; Rai S; Sorotsky H; Herman M; Shepshelovich D; Bruce J; Liang M; Patel D; Cheng D; Chen Z; Eng L; Brown MC; Cho J; Leighl NB; de Perrot M; Reisman D; Xu W; Bradbury PA; Liu G
    Mol Carcinog; 2019 Nov; 58(11):1960-1973. PubMed ID: 31355511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial.
    Liu G; Cuffe S; Liang S; Azad AK; Cheng L; Brhane Y; Qiu X; Cescon DW; Bruce J; Chen Z; Cheng D; Patel D; Tse BC; Laurie SA; Goss G; Leighl NB; Hung R; Bradbury PA; Seymour L; Shepherd FA; Tsao MS; Chen BE; Xu W; Reisman DN
    Clin Cancer Res; 2017 May; 23(10):2460-2470. PubMed ID: 27827316
    [No Abstract]   [Full Text] [Related]  

  • 3. Association of BRM promoter polymorphisms and esophageal adenocarcinoma outcome.
    Korpanty GJ; Eng L; Qiu X; Faluyi OO; Renouf DJ; Cheng D; Patel D; Chen Z; Tse BC; Knox JJ; Dodbiba L; Teichman J; Azad AK; Wong R; Darling G; Reisman D; Cuffe S; Liu G; Xu W
    Oncotarget; 2017 Apr; 8(17):28093-28100. PubMed ID: 28427211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two BRM promoter insertion polymorphisms increase the risk of early-stage upper aerodigestive tract cancers.
    Wong KM; Qiu X; Cheng D; Azad AK; Habbous S; Palepu P; Mirshams M; Patel D; Chen Z; Roberts H; Knox J; Marquez S; Wong R; Darling G; Waldron J; Goldstein D; Leighl N; Shepherd FA; Tsao M; Der S; Reisman D; Liu G
    Cancer Med; 2014 Apr; 3(2):426-33. PubMed ID: 24519853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low homozygous/high heterozygous deletion status by p16 FISH correlates with a better prognostic group than high homozygous deletion status in malignant pleural mesothelioma.
    Hamasaki M; Matsumoto S; Abe S; Hamatake D; Kamei T; Hiroshima K; Kawahara K; Sato A; Tsujimura T; Nakatani Y; Yoshida Y; Iwasaki A; Nabeshima K
    Lung Cancer; 2016 Sep; 99():155-61. PubMed ID: 27565933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two BRM promoter polymorphisms predict poor survival in patients with hepatocellular carcinoma.
    Pasic I; Wong KM; Lee JJ; Espin-Garcia O; Brhane Y; Cheng D; Chen Z; Patel D; Brown C; Bucur R; Reisman D; Knox JJ; Xu W; Hung RJ; Liu G; Cleary SP
    Mol Carcinog; 2018 Jan; 57(1):106-113. PubMed ID: 28892201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.
    Zauderer MG; Bott M; McMillan R; Sima CS; Rusch V; Krug LM; Ladanyi M
    J Thorac Oncol; 2013 Nov; 8(11):1430-3. PubMed ID: 24128712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma.
    Cheng YY; Kirschner MB; Cheng NC; Gattani S; Klebe S; Edelman JJ; Vallely MP; McCaughan BC; Jin HC; van Zandwijk N; Reid G
    J Thorac Oncol; 2013 Oct; 8(10):1317-28. PubMed ID: 24457242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two novel BRM insertion promoter sequence variants are associated with loss of BRM expression and lung cancer risk.
    Liu G; Gramling S; Munoz D; Cheng D; Azad AK; Mirshams M; Chen Z; Xu W; Roberts H; Shepherd FA; Tsao MS; Reisman D
    Oncogene; 2011 Jul; 30(29):3295-304. PubMed ID: 21478907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The homeobox gene EMX2 is a prognostic and predictive marker in malignant pleural mesothelioma.
    Giroux Leprieur E; Hirata T; Mo M; Chen Z; Okamoto J; Clement G; Li H; Wislez M; Jablons DM; He B
    Lung Cancer; 2014 Sep; 85(3):465-71. PubMed ID: 25023662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene-asbestos interaction in malignant pleural mesothelioma susceptibility.
    Tunesi S; Ferrante D; Mirabelli D; Andorno S; Betti M; Fiorito G; Guarrera S; Casalone E; Neri M; Ugolini D; Bonassi S; Matullo G; Dianzani I; Magnani C
    Carcinogenesis; 2015 Oct; 36(10):1129-35. PubMed ID: 26139392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylation-associated Silencing of microRNA-126 and its Host Gene EGFL7 in Malignant Pleural Mesothelioma.
    Andersen M; Trapani D; Ravn J; Sørensen JB; Andersen CB; Grauslund M; Santoni-Rugiu E
    Anticancer Res; 2015 Nov; 35(11):6223-9. PubMed ID: 26504055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
    Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
    Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Upregulation of microRNA-31 associates with a poor prognosis of malignant pleural mesothelioma with sarcomatoid component.
    Matsumoto S; Nabeshima K; Hamasaki M; Shibuta T; Umemura T
    Med Oncol; 2014 Dec; 31(12):303. PubMed ID: 25358615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BAP1 immunohistochemistry has limited prognostic utility as a complement of CDKN2A (p16) fluorescence in situ hybridization in malignant pleural mesothelioma.
    McGregor SM; McElherne J; Minor A; Keller-Ramey J; Dunning R; Husain AN; Vigneswaran W; Fitzpatrick C; Krausz T
    Hum Pathol; 2017 Feb; 60():86-94. PubMed ID: 27771374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in DNA repair genes predispose asbestos-exposed patients to malignant pleural mesothelioma.
    Betti M; Casalone E; Ferrante D; Aspesi A; Morleo G; Biasi A; Sculco M; Mancuso G; Guarrera S; Righi L; Grosso F; Libener R; Pavesi M; Mariani N; Casadio C; Boldorini R; Mirabelli D; Pasini B; Magnani C; Matullo G; Dianzani I
    Cancer Lett; 2017 Oct; 405():38-45. PubMed ID: 28687356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
    Johnson TG; Schelch K; Cheng YY; Williams M; Sarun KH; Kirschner MB; Kao S; Linton A; Klebe S; McCaughan BC; Lin RCY; Pirker C; Berger W; Lasham A; van Zandwijk N; Reid G
    J Thorac Oncol; 2018 Feb; 13(2):258-272. PubMed ID: 29113949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival.
    Bahnasy AA; El-Din RS; Sabri NA; Abdel-Rahman CA; Bastawisy AE
    Cancer Genet; 2018 Dec; 228-229():83-92. PubMed ID: 30553477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic analysis in short- and long-term patients with malignant pleura mesothelioma treated with palliative chemotherapy.
    Torricelli F; Saxena A; Nuamah R; Neat M; Harling L; Ng W; Spicer J; Ciarrocchi A; Bille A
    Eur J Cancer; 2020 Jun; 132():104-111. PubMed ID: 32339978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two functional indel polymorphisms in the promoter region of the Brahma gene (BRM) and disease risk and progression-free survival in colorectal cancer.
    Yu Y; Cheng D; Parfrey P; Liu G; Savas S
    PLoS One; 2018; 13(6):e0198873. PubMed ID: 29894502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.